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A total of 566 patients with vaficeal bleeding caused by cirrhosis of the liver, noncirrhotic portal fi-
brosis (NCPF) and extrahepatic portal venous obstruction (EHO) were treatedby repeated endoscopic
injection sclerotherapy. This decreased rebleeding was evidenced by a reduction in mean bleeding
risk factor and transfusion requirement. Both the factors were significantly (P < 0.001) decreased in
all three groups of patients. Rebleeding occurred before eradication in 27.7% of patients with cir-
rhosis, 24.3% of those with NCPF, and 11% of those with EHO. Significantly more patients with cir-
rhosis and NCPF bled in comparison to EHO. Irrespective of the etiology, fewer patients of Child’s
A class bled than those of Child’s B andC classes (P < 0.001). The median bleeding-free period was
longer in patients withEHO than in those with cirrhosis (P< 0.05). This period was also significantly
longer in Child’s A class than in Child’s B and the latter had a longer median bleeding-free period
than Child’s C class (P < 0.01). Variceal eradication was achieved in 80% of patients with cirrhosis,
87% of patients with NCPF, and 90% of patients with EHO. The success of variceal eradication was
higher inEHO patients in contrast with patients with cirrhosis of the liver. Similarly, eradication was
better in Child’s A class patients than in Child’s B and C class patients. Recurrence of varices and
complications were not influenced by the Child’s status or etiology of portal hypertension. The prob-
ability of survival at 10 years was higher in patients with EHO (88%) and NCPF (80%) than in pa-
tients with cirrhosis (50%). Similarly, patients with Child’sA (88%) status survived longer than those
with Child’ s B (42%) status, and patients with Child’ s B status had a longer survival than Child’ s C
status patients (0%). Thus, endoscopic variceal sclerotherapy appears to be a useful procedure for the
long-term management of patients after an esophageal variceal bleeding irrespective of the etiology
of portal hypertension.
KEY WORDS: Endoscopic sclerotherapy for esophageal varices, cirrhosis of the liver, noncirrhotic portal
fibrosis, extrahepatic portal venous obstruction
INTRODUCTION
Since 1981,wehavebeen injectingesophageal varices dur-
ing active varicealbleedingand forlong-termmanagement
after variceal bleeding (1-4). In India, besides cirrhosis of
the liver, two other diseases, noncirrhotic portal fibrosis
(NCPF), andextrahepatic portalvenous obstruction(EHO)
are also responsible for portal hypertension (5).
Between 1981 and 1993, we treated 566 patients with
portal hypertension, who had bleeding from esophageal
varices. The varices were caused by cirrhosis of the liver,
NCPF, and EHO. These are few studies on the long-term
results of the use of endoscopic sclerotherapy (EST) for
the management of patients who had bled from esopha-
gastic varices as in the present study. The efficacy of this
mode of treatment is retrospectively reviewed. This study
also compares the results among the three groups of pa-
tients. This is one ofthe largest groups ofpatients reported
with a long and complete follow-up.
METHODS
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Between January 1981 and June 1993, 566 consecutive
patients with portal hypertension underwent EST of
esophageal varices: 342 with cirrhosis of the liver, 107212 D.K. BHARGAVA et al.
with NCPF and 117 with EHO (Table 1). The etiology of
cirrhosiswas alcohol-related in 119, posthepatic in 91, and
cryptogenic in 132 patients. Informed consent was ob-
tained from all patients. All of them were seen with en-
doscopically documented variceal hemorrhage requiring
blood transfusion in the recent past (< 30 days).
In each patient endoscopy confirmed grade 3 or 4
esophageal varices (6). All patients had a detailed clinical
evaluation. Hepatic cirrhosis was verified by liver biopsy
orconsidered the most likely diagnosis on the basis ofclin-
ical, biochemical, and imaging criteria. The diagnosis of
NCPF was established by the exclusion of cirrhosis of the
liver on histologic examination and EHO. The diagnosis
of EHO was made on ultrasound and/or splenopor-
tovenogram. The hepatic functional reserve was classified
by the Pugh’s modification of the Child’s scoring system
(7). Variceal rebleeding was defined by a definite history
of hematemesis and melena with endoscopic evidence of
active bleeding or the presence ofvarices with no other le-
sion in the upper gastrointestinal tract (1).
Technique
Sclerotherapy was carried out using an Olympus Q10,
XQ10, XQ20, or video forward-viewing fiberoptic pan-
endoscope andNM-1K injector. Polidocanol 1% solution
(Aethoxysklerol, Krussler & Co., Germany) was used as
a sclerosing agent. The technique of injection has already
been described in detail (1). The injections were repeated
every 3 weeks until July 1991. Subsequently, the varices
were injected weekly. After eradication, endoscopic ex-
amination was repeated every 3 to 6 months to observe
Table I Patient characteristics.
Cirrhosis NCPF EHO
No. 342 107 117
M/F 302/40 77/30 76/41
Age(yr.) 43.6 + 19.8 29.8 + 14.6 15.1 + 8.9
(mean :t: SD)
Child’s score
A 114 90 117
B 180 17
C 48
any recurrence of varices. The new varices were injected
in a similar manner until eradication was achieved.
Statistical Methods
The qualitative variables were analyzed using the Z
2 test.
Quantitative variables were analyzed by Student’s test
and those with skewed values by Wilcoxon’s rank-sum
test. The Kaplan-Meier method was used to estimate the
probabilities of survival and bleeding-free period. The re-
sulting curves were compared using the log-rank test.
RESULTS
Before the initiation ofEST, the episodes ofbleeding and
blood transfusion requirements were similar in the pa-
tients with cirrhosis, NCPF, and EHO (P > 0.1).
Rebleeding before and after EST was compared using 1)
mean bleeding risk factor (BRF), defined as the number
of rebleeding episodes per patient per month of follow-
up; and 2) mean transfusion requirements. Both were sig-
nificantlt (P < 0.001) decreased in all three groups of
patients afterEST (Table 2). Patients with cirrhosis of the
liver, NCPF, and EHO were followed for a mean period
of 64, 72, and 73 months respectively. Nineteen percent
ofpatients were lost to follow-up during the study period.
Patients lost to follow-up were analyzed up to the point
they were last seen.
Rebleeding Parameters
Patients Rebleeding
The numbers ofpatients whose varices rebledbetween the
first session of EST and eradication in the different etio-
logical subgroups and stratified for Child’s scores are
given in Table 3. Significantly more patients with cirrho-
sishadrebleeding (27.7%)comparedwith those withEHO
(P< 0.0001). The number ofpatients withNCPFwho had
rebleeding (24.3%) was significantlymore (P< 0.05) than
those with EHO (11.1%). There was no difference in the
rebleeding ratesbetween patients with cirrhosis andNCPF
(P > 0.1).
Table 2 Comparison of Rebleeding Parameters
Mean BRF Mean Transfusion
Before EST AfterEST P Value Before EST AfterEST P Value
Cirrhosis 0.41 0.027 <0.001
NCPF 0.16 0.008 <0.001
EHO 0.12 0.005 <0.001
BRF: Bleeding risk factor; EST: Endoscopic sclerotherapy
6.4 _+ 6.1 2. _
1.6 <0.001
7.1 + 5.9 1.3 2.3 <0.001
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Table 3 Number of Patients and Episodes of Rebleeding
Etiology A B C Total
Cirrhosis 24 46 25 95 (27.7%)
(30) (51) (48) (129)
NCPF 17 9 0 26 (24.3%)
(28) (22) (50)
EHO 13 0 0 13 (11.1%)
(18) (18)
Total 54 (16.8%) 55 (27.9%) 25 (52.08%)
Figures in parentheses indicate number of episodes of rebleeding.
Analysis of the influence of Child’s status irrespective
of etiology showed that significantly fewer patients of
Child’sA class (16.8%) bled than those of Child’s B class
(27.9%) or Child’s C class (52.08%) while patients of
Child’s B status bled less than those ofChild’s C status (P
< 0.001).
Bleeding-Free Period
The probability ofthe bleeding-free period (BFP) was cal-
culated by the Kaplan-Meier method. This was signifi-
cantly longer (Fig. 1) in patients withEHO (>120 months)
than in those with cirrhosis (P < 0.05). There was no sig-
nifican difference in the median BFP (P > 0.1) between
patients with cirrhosis (> 120 months) and NCPF (> 120
months). The etiology of portal hypertension did not af-
fect the BFP for a given Child’s class of patients. Patients
of Child’s A status (Fig. 2) irrespective of etiology had a
longer BFP (> 19 months) in contrast to Child’s B (> 98
months) or C (> 12 months) patients. Similarly, patients
in Child’s B class had a longer BFP than those in Child’s
C class (P < 0.01).
Variceal Eradication and Recurrence
Variceal eradication was achieved in 274 patients with cir-
rhosis (80%), 79 patients with NCPF (87%), and 105 pa-
tients with EHO (90%). The success of eradication was
significantly higher in patients with EHO than in those
with cirrhotics (P < 0.05). This was also related to the
Child’s status ofpatients, as eradication occurred in 88.8%
ofpatients having a Child’sA status and 76.3% among the
Child’s B and C group. There was no difference among
patients having similar Child’s status within different eti-
ologic subgroups (P > 0.05). The mean number of ses-
sions of EST required for eradication was 7.9 (+3.8) in
patients with cirrhosis, 7.6 (+3.2) in those with NCPF, and
7.4 (+3.6) in those with EHO and were similar (P > 0.1).
Recurrence ofesophageal varices was observed in 21%
of patients and was not affected by the etiology of portal
hypertension orthe Child’s score (P> 0.05). Ofthese, 21%
ofpatients with recurrence ofvarices, 26% were seen with
variceal bleeding. Recurrences were observed afteramean
period of 38.9 + 22.6 months and were between grade 1
and grade 2 at the onset. These were reinjectedby the same
technique until eradication (mean 1.3 sessions).
Causes of Death
There were 89 (26%) deaths among patients with cirrho-
sis of the liver. Seven (6.5%) patients with NCPF and 2
(1.70%) patients with EHO died on follow-up. In patients
with cirrhosis of the liver, hepatic encephalopathy was the
direct major cause of death in 65 patients, uncontrolled
variceal bleeding in 15, spontaneous bacterial peritonitis
in 2, hepatorenal syndrome in 3, septicemia in 3, and he-
patocellular carcinoma in 1. Among patients with NCPF,
four died ofa combination of variceal hemorrhage and he-
patic coma. The remaining patients with NCPF and EHO
died of exsanguinating hemorrhage. There were 8 (7%) of
Child’s A, 51 (28.33%) of Child’s B, and 30 (62.5%) of
Child’sC class patients with cirrhosiswho died. Therewere
two deaths (2.2%) among patients with NCPF of Child’s
A class and 5 (29.41%) of Child’s B class. The mortality
was significantly lower (P < 0.01) in patients of Child’sA
class than in patients ofChild’sB class and lowerin Child’s
B thanC class (P < 0.01) patients, irrespective of etiology.
Survival
An analysis ofthe survival by the Kaplan-Meier technique
showed that the probability of survival at 10 years was 50,
80, and 88% in patients with cirrhosis, NCPF, and EHO,
respectively (Fig. 3). Patients with NCPF and EHO sur-
vived longer than patients with cirrhosis (P< 0.01). There
was no statistical differences between patients withNCPF
andEHO (P> 0.05). The probabilityofsurvival at 10years
was 88% for Child’s A,42% Child’s B, and0% for Child’s
C class patients (Fig. 4). Patients belonging to Child’s A
status irrespective ofetiologyhad significantly (P< 0.001)
longer survival than those ofChild’sB orC class. Similarly
patients of Child’s B status survived longer than those of
Child’s C status (P < 0.01).
Complications
Complications such as retrosternal pain, fever of> 100F,
deep ulcers, dysphagia, stricture, mediastinitis, pneumo-
nia, and pleural effusions were observed in 15% ofour pa-
tients after EST. The Child’s status and the etiology of
portal hypertension did not influence the incidence of
complications significantly. Mucosal slough or local su-
perficia ulcers were excluded from the list of complica-
tions as they were usually of little significance in the
overall management of the patients.214 D.K. BHARGAVA et al.
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Bleeding-free period after EST: this was significantly longer in patients with EHO than in those with cirrhosis of the liver.
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Figure 2 Bleeding-free period after EST: patients of Child’s A status had a longer bleeding-free period compared with Child’s B orC status patients
and patients of Child’s B class had longer than patients with Child’s C class.LONG TERM MANAGEMENT OF ESOPHAGEAL VARICES BY EST 215
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Figure 3 Cumulative survival rates after sclerotherapy by life for patients with EHO, NCPF, and cirrhosis. Patients with EHO and NCPF survived
longer than those with cirrhosis.
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Figure 4 Cumulative survival rates after sclerotherapy for patients according to their Child’s status. Patients of Child’s A class survived longer than
those of Child’s C class. Survival was longer in patients of Child’s B class than those of Child’ C class.216 D.K. BHARGAVA et al.
DISCUSSION
Repeated sclerotherapy has been found to be a safe and
effectivemode oftreatmentfor the long-termmanagement
of esophageal variceal bleeding irrespective of the etiol-
ogyofportal hypertension. This is supportedby controlled
and prospective trials (1-3,8,9). The place oflong-term 13-
blockade remains controversial (10). Surgical procedures
have significant morbidity and mortality.
One of the major disadvantages of repeated EST was
rebleeding episodes before eradication of varices. These
occurred more often in patients of Child’s C status than in
those of Child’s B class and more in Child’s B status than
Child’s A status patients in the present study. Similarly,
patients with better hepatic function had a significantly
longer BFP. In terms of etiology, results ofrebleeding pa-
rameters favored patients withEHO more than those with
NCPF and cirrhosis ofthe liver. This was supported by the
observation that there was no significant difference be-
tween different etiologic categories within each Child’s
class. Similar observations have been made by Sakai et al.
(11) reported better results in patients with schistosomia-
sis than in those with cirrhosis.
It was observed that rebleeding episodes were in-
significant once the varices are eradicated. This was
achieved in 80% of patients with cirrhosis, 87% of pa-
tients with NCPF, and 90% of patients with EHO. The
mean number of sclerotherapy sessions required for erad-
ication were comparable in the three groups. Eradication
rate was better achieved in Child’s A class patients than
in Child’sB and Child’sC class patients (P< 0.05). It was
difficult to eradicate varices in the remaining patients, and
in many ofvarices continue to bleed intermittently. These
should be considered as sclerotherapy failures. Such pa-
tients should probably be subjected to an alternate proce-
dure such as surgery or endoscopic band ligation.
Terblanche et al. (9) also reported that 10% of their pa-
tients failed to respond to sclerotherapy. The recurrence
of varices was observed in 21% of patients after a mean
period of 38.9 + 22.6 months irrespective of etiology or
Child’s status. The lower incidence of recurrence in our
series was possibly due to total eradication of varices at
the begining of treatment and a regular follow-up of pa-
tients at an interval of 3 to 6 months. Thus, prevention of
recurrent bleeding was dependent upon the successful
eradication of varices, and regular surveillance is neces-
sary to ensure eradication.
It is not yet clear whether repeated sclerotherapy im-
proves survival. Meta analysis of the data from controlled
trials did, however, show a survival advantage for scle-
rotherapy (12). The overall cumulative survival rate at 10
years was 50, 80, and 88% in patients with cirrhosis of the
liver, NCPF, and EHO, respectively. The cumulative 10-
year survival rate was 88% for Child’s A, 42% for Child’s
B, and0% forChild’sC class patients. As expectedChild’s
status of the patients did influence the survival. The etiol-
ogy ofthe patients also influenced survival as patients with
EHO and NCPF survived longer than those with cirrho-
sis. This could be because the majority of patients with
NCPF and EHO belonged to Child’s A status. This ob-
servation was similar to that of others (9,11) and has also
been emphasized by us in the past (1).
Usually, complications related to the procedure were
minor except for esophageal stricture formation, medias-
tinitis, pleural effusion, and pneumonia. Superficial ulcers
andmucosal sloughwere oflittle significance as they were
only encountered during repeated endoscopy. It is sug-
gested that this leads to better eradication of varices and
control of recurrent bleeding episodes (13,14).
Complications alsovarywiththe type ofsclerosant(15,16)
used as well as the quantity, concentration, and frequency
of injections (17).
Thus, the present study confirms that repeated endo-
scopic sclerotherapy prevents rebleedingby eradication of
varices. The results were influenced primarily by the func-
tional hepatic status and indirectly by the etiology of por-
tal hypertension. Eradication is most successful in patients
with EHO, followed byNCPF and cirrhosis ofthe liver. It
is difficult to comment whether eradication of varices in-
creases the survival. However, at least patients with EHO
and NCPF have an excellent survival rate. On the basis of
ourobservations, repeatedendoscopic sclerotherapy is the
procedure of choice for the long-term management of
esophageal varices at our center, irrespective of the etiol-
ogy of portal hypertension and their functional status. We
are injecting varices everyweekwith 1% polidocanol until
they are eradicated. In case of failure of sclerotherapy, we
resort to either endoscopic band ligation or surgery. Once
the vadces are eradicated, endoscopy is performed at an
interval of 3 to 6 months to detect early recurrence of
varices. Recurrent vadces should be treated similarly.
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